The impact of drug–drug interactions on pulmonary arterial hypertension therapy
- 1 June 2014
- journal article
- review article
- Published by Elsevier in Pulmonary Pharmacology & Therapeutics
- Vol. 28 (1) , 1-8
Abstract
No abstract availableKeywords
This publication has 38 references indexed in Scilit:
- Drug Interactions With Phosphodiesterase-5 Inhibitors Used for the Treatment of Erectile Dysfunction or Pulmonary HypertensionCirculation, 2010
- Development and Pathology of Pulmonary HypertensionJACC, 2009
- Updated Evidence-Based Treatment Algorithm in Pulmonary Arterial HypertensionJACC, 2009
- Role of OATP Transporters in the Disposition of DrugsPharmacogenomics, 2007
- Evaluation and Management of the Patient with Pulmonary Arterial HypertensionAnnals of Internal Medicine, 2005
- Prostanoid therapy for pulmonary arterial hypertensionJACC, 2004
- Nitric oxide pathway and phosphodiesterase inhibitors in pulmonary arterial hypertensionJACC, 2004
- Cellular and molecular pathobiology of pulmonary arterial hypertensionJACC, 2004
- Implications of Cytochrome P450 Interactions When Prescribing Medication for HypertensionArchives of internal medicine (1960), 2002
- CYP3A genetics in drug metabolismNature Medicine, 2001